Provided by Tiger Trade Technology Pte. Ltd.

Jazz Pharmaceuticals PLC

250.68
+6.142.51%
Volume:1.22M
Turnover:305.50M
Market Cap:16.27B
PE:17.14
High:252.72
Open:241.39
Low:241.39
Close:244.54
52wk High:266.38
52wk Low:123.88
Shares:64.91M
Float Shares:62.69M
Volume Ratio:0.59
T/O Rate:1.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):14.63
EPS(LYR):-5.8403
ROE:22.11%
ROA:6.86%
PB:3.39
PE(LYR):-42.92

Loading ...

Earning Preview: Jazz Pharmaceuticals PLC Q1 revenue is expected to decrease by 0.67%, and institutional views are cautious to neutral

Earnings Agent
·
Apr 28

TD Cowen Sticks to Their Buy Rating for Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Apr 27

Jazz Pharmaceuticals Announces FDA Acceptance And Priority Review Of Supplemental Biologics License Application For Ziihera®

Reuters
·
Apr 27

Jazz Pharma FDA wins priority review for Ziihera combos in first-line HER2+ GEA

Reuters
·
Apr 27

Jazz Pharmaceuticals Plc - FDA Sets Pdufa Date of August 25, 2026 for Ziihera Sbla

THOMSON REUTERS
·
Apr 27

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (Zanidatamab-Hrii) Combinations in First-Line Her2+ Locally Advanced or Metastatic Gea

THOMSON REUTERS
·
Apr 27

Jazz Pharmaceuticals Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Apr 22

Jazz Pharmaceuticals to report first-quarter results after market close

Reuters
·
Apr 22

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026

THOMSON REUTERS
·
Apr 22

Jazz spotlights Phase 3 HERIZON-GEA-01 PD-L1 subgroup data for Ziihera at ASCO

Reuters
·
Apr 22

Jazz Pharmaceuticals Is Maintained at Overweight by Barclays

Dow Jones
·
Apr 20

A Look At Jazz Pharmaceuticals (JAZZ) Valuation After New Neurology Data Plans At 2026 AAN Meeting

Simply Wall St.
·
Apr 16

Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says

MT Newswires Live
·
Apr 09

Jazz reports EpiCom analysis shows Epidiolex cuts behavioral problems in TSC seizures

Reuters
·
Apr 09

RBC Capital Remains a Buy on Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Apr 08

Jazz director Bruce C. Cozadd disposes of Jazz Pharma shares worth $1.1 million

Reuters
·
Apr 04

Jazz Pharmaceuticals to present at Needham Virtual Healthcare Conference

Reuters
·
Apr 02

BRIEF-Pharma Mar Receives Positive Opinion From EMA Recommending Approval Of Zepzelca With Atezolizumab

Reuters
·
Mar 27

Pharma Mar - Phase 3 Imforte Trial, Sponsored by Roche in Collaboration With Jazz Pharmaceuticals

THOMSON REUTERS
·
Mar 27

How New Ziihera and JZP898 Data from AACR 2026 Will Impact Jazz Pharmaceuticals (JAZZ) Investors

Simply Wall St.
·
Mar 22